ArticleScientific reports2025
Pharmacological Evaluation of active compounds in papaya associated with thrombocytopenia inhibition in dengue patients through in silico approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the therapeutic potential of five natural compounds from Carica papaya - olean-12-ene, quercetin, apigenin, luteolin and kaempferol - against dengue virus (DENV) using a multi-faceted in silico approach. Quantum chemical analysis using density functional theory (DFT) revealed insights into the electronic properties and stability, with olean-12-ene exhibiting the highest stability (HOMO-LUMO gap: 6.91 eV), while luteolin and apigenin showed balanced reactivity profiles suitable for biochemical interactions. ADMET profiling underlined the drug-likeness of these compounds: Quercetin showed good solubility (logS: -2.93) and hydrogen bonding potential, apigenin showed high oral bioavailability (HIA: 93.25%) and olean-12-ene exhibited remarkable permeability (Caco-2: 1.26). Molecular docking simulations against the DENV NS2B-NS3 protease, the NS1 protein and the envelope protein provided further insight into their binding affinities and interaction modes. Toxicity assessments indicated manageable risks, although flavonoids exhibited moderate hepatotoxicity and olean-12-ene showed cardiotoxic/nephrotoxic tendencies, suggesting a need for further optimization. Overall, these results highlight the potential of specific papaya-derived compounds, particularly the flavonoids, as candidates for further experimental validation in the development of anti-DENV therapeutics. This work lays a foundation for future in vitro and in vivo studies to combat DENV infection and associated complications such as thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.